Arrowhead Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 4/4
Arrowhead Pharmaceuticals CEO'su Chris Anzalone, Dec2007 tarihinde atandı, in görev süresi 18.75 yıldır. in toplam yıllık tazminatı $ 9.03M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.9% maaş ve 89.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.69% ine doğrudan sahiptir ve bu hisseler $ 313.89M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 14.8 yıldır.
Anahtar bilgiler
Chris Anzalone
İcra Kurulu Başkanı
US$9.0m
Toplam tazminat
| CEO maaş yüzdesi | 10.86% |
| CEO görev süresi | 18.8yrs |
| CEO sahipliği | 2.7% |
| Yönetim ortalama görev süresi | 3.4yrs |
| Yönetim Kurulu ortalama görev süresi | 14.8yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Sep 03
ARWR: Phase 3 SHASTA Results And Voucher Plan Will Drive Repricing
Analysts have lifted Arrowhead Pharmaceuticals' fair value estimate from $85.00 to $100.00. They cite stronger conviction around plozasiran in severe hypertriglyceridemia, the Madrigal partnership, and recent Phase 3 SHASTA-3 and SHASTA-4 data that underpin higher projected profit margins despite slightly softer revenue growth assumptions and a higher future P/E.
Anlatı Güncellemesi • Aug 19
ARWR: SHTG Phase 3 Success And PRV Use Will Drive Future Upside
Arrowhead Pharmaceuticals' updated analyst price target has moved from about $89 to about $110. Analysts point to stronger assumptions around plozasiran in severe hypertriglyceridemia, the Madrigal partnership and the planned $215m priority review voucher purchase as key drivers of the revised valuation inputs.
Anlatı Güncellemesi • Aug 05
ARWR: Cardiometabolic RNAi Readouts In Severe Hypertriglyceridemia Will Drive Future Repricing
Arrowhead Pharmaceuticals' updated analyst price target of $126, up from $110, reflects analysts' higher modeled revenue growth and confidence in plozasiran following positive SHASTA-3 and SHASTA-4 Phase 3 data. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals shows a cluster of higher price targets and supportive commentary tied directly to the Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia.Seeking Alpha • Jul 22
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials
Summary Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions and significant acute pancreatitis risk reduction in severe hypertriglyceridemia. Redemplo demonstrates strong efficacy, quarterly dosing, and a favorable safety profile versus Ionis’ Tryngolza, positioning ARWR for leadership in the SHTG market. Tryngolza has a first-mover advantage and administration with an autoinjector versus the current prefilled syringe for Redemplo, but ARWR expects to have an autoinjector as well. I expect modest near-term sales from the small FCS market, with significant revenue potential upon SHTG launch following sNDA submission and likely approval by late 2027. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jul 21
ARWR: Upcoming SHASTA-3 And 4 Results Will Drive Bullish Repricing
Arrowhead Pharmaceuticals' updated fair value estimate has been lifted from $57.11 to $85.00 as analysts factor in higher Street price targets in the $95 to $98 range, supported by growing optimism around upcoming SHASTA-3/4 data for plozasiran and its potential in severe hypertriglyceridemia. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals centers on the upcoming SHASTA-3/4 data readout for plozasiran in severe hypertriglyceridemia, with several firms updating price targets as they reassess the company’s risk and opportunity profile.Anlatı Güncellemesi • Jul 07
ARWR: Cardiometabolic Progress And EU Approval Will Support But Not Eliminate SHTG Uncertainty
Arrowhead Pharmaceuticals' analyst price targets have moved higher into the mid $40s, with analysts pointing to updated assumptions on fair value, profitability and revenue trends as key reasons for the reset. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals points to a cluster of price target increases and rating changes that frame how analysts are thinking about valuation, execution risk, and growth potential at current levels in the mid $40s.Anlatı Güncellemesi • Jun 23
ARWR: Mixed Wave Data And Execution Risks Will Challenge Recent Rebound
Analysts have lifted their price expectations for Arrowhead Pharmaceuticals. The updated fair value estimate has moved from $42.57 to $57.11 as they factor in a slower anticipated revenue decline, a higher projected profit margin, and a slightly lower future P/E multiple.Analiz Makalesi • Jun 20
Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update
Arrowhead Pharmaceuticals (ARWR) recently outlined a Summer Series of R&D webinars focused on its cardiometabolic pipeline, alongside positive clinical updates and upcoming regulatory milestones that have drawn fresh attention to the stock. See our latest analysis for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals’ recent R&D webinar announcement and positive late May clinical readouts have coincided with strong momentum, including a 45.25% 3 month share price return and a very large 1...Anlatı Güncellemesi • Jun 08
ARWR: Cardiometabolic RNAi Readouts And Licensing Will Drive Future Repricing
Arrowhead Pharmaceuticals' updated analyst price target moves to $46, up from $35, as analysts factor in modestly higher long term growth and margin assumptions, along with a slightly lower discount rate, while keeping fair value unchanged at $110. Analyst Commentary Recent Street research around Arrowhead points to a constructive shift in tone, with a series of bullish analysts highlighting upside drivers tied to execution on the pipeline and the broader biotech backdrop.Anlatı Güncellemesi • May 25
ARWR: Cardiometabolic RNAi Data And Licensing Will Drive Future Repricing
Analysts have raised Arrowhead Pharmaceuticals' average price target by $11 to $46, citing a stronger sector backdrop, healthier biotech funding conditions, and reassessed growth and profitability assumptions. These are reflected in higher revenue growth expectations and a slightly higher future P/E multiple.Anlatı Güncellemesi • May 07
ARWR: Cardiometabolic RNAi Data And Licensing Progress Will Drive Future Repricing
Analysts have raised their Arrowhead Pharmaceuticals price target by $12 to $110, citing updated assumptions for a less severe revenue contraction, higher projected profit margins, and a lower forward P/E estimate in recent research. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals has reflected a mix of caution and renewed optimism, with several bullish analysts focusing on price target changes, upgrades, and the implications for valuation and execution risk.Anlatı Güncellemesi • Apr 21
ARWR: Wave Data Concerns Will Test Sustainability Of Recent Share Price Rebound
Arrowhead Pharmaceuticals' analyst price target has edged higher by about $0.26 to $42.57, with analysts pointing to updated views on profit margins and P/E assumptions following a mix of recent target raises and trims across the Street. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals reflects a split view, with some firms lifting targets sharply and others trimming expectations.Anlatı Güncellemesi • Apr 06
ARWR: RNAi Obesity And Cardiometabolic Data Will Drive Future Repricing
Narrative update on Arrowhead Pharmaceuticals The consensus analyst price target for Arrowhead Pharmaceuticals has been adjusted to $110. This reflects mixed recent research that pairs questions around Wave Life Sciences data with higher targets from several firms citing early obesity program results and the Redemplo launch.Anlatı Güncellemesi • Mar 23
ARWR: Obesity RNAi Data And Cardiometabolic Franchise Will Drive Future Repricing
Analysts have updated their views on Arrowhead Pharmaceuticals with a revised blended price target of $110. This reflects mixed shifts in assumptions around discount rate, revenue growth, profit margins and future P/E after recent obesity and cardiometabolic data, as well as the Redemplo launch.Anlatı Güncellemesi • Mar 09
ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Price Rebound
Analysts have reduced their blended price target on Arrowhead Pharmaceuticals by about $2 to reflect a lower fair value estimate of $42.31. This incorporates more cautious assumptions on near term revenue growth and margins, even as recent research notes highlight supportive early obesity data and emerging cardiometabolic opportunities.Anlatı Güncellemesi • Feb 22
ARWR: Obesity And Cardiometabolic Pipeline Progress Will Drive Future Repricing
Narrative Update: Arrowhead Pharmaceuticals The updated analyst price framework for Arrowhead Pharmaceuticals keeps fair value at $110 while trimming implied future P/E assumptions, reflecting analysts' mixed but generally constructive reaction to recent obesity and cardiometabolic data and the Redemplo launch. Analyst Commentary Recent research updates on Arrowhead Pharmaceuticals cluster around two themes you should keep in mind: confidence in the obesity and cardiometabolic pipeline, and growing interest in the early commercial rollout of Redemplo.Analiz Makalesi • Feb 12
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality
Arrowhead Pharmaceuticals, Inc.'s ( NASDAQ:ARWR ) earnings announcement last week was disappointing for investors...Anlatı Güncellemesi • Feb 08
ARWR: Obesity Pipeline Progress Will Drive Future Repricing In My View
Analysts raised their fair value estimate for Arrowhead Pharmaceuticals to $110 from $80 as they incorporate updated assumptions on Redemplo's launch, initial obesity pipeline data, and a lower projected future P/E multiple, while also reflecting slightly higher risk and more conservative expectations for revenue growth. Analyst Commentary Bullish analysts are leaning into Arrowhead's transition from a pure development story toward one with its first approved product and an emerging obesity pipeline, and they are adjusting their models to reflect both assets.Anlatı Güncellemesi • Jan 25
ARWR: Early Obesity RNAi Data Will Challenge Durability Of Recent Share Repricing
Narrative update on Arrowhead Pharmaceuticals The updated analyst price target for Arrowhead Pharmaceuticals shifts to reflect a fair value of $44.02. Analysts point to Redemplo's approval and launch, early data from the ARO INHBE and ARO ALK7 obesity programs, and increased confidence in the pipeline as key factors in their revised outlook.Anlatı Güncellemesi • Jan 11
ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Repricing
Arrowhead Pharmaceuticals' analyst fair value estimate moved from $17.00 to about $44.94, as analysts cited early obesity trial data for ARO INHBE and ARO ALK7, validation of the TRiM RNAi platform, and the first FDA approval of Redemplo as key reasons for higher price targets in the US$80 range. Analyst Commentary Street research around Arrowhead has tilted more constructive around the obesity franchise, with multiple firms lifting their fair value estimates into the US$80 range after the initial ARO INHBE and ARO ALK7 data.Anlatı Güncellemesi • Dec 18
ARWR: Upcoming SHTG Readouts Will Temper Optimism Despite Recent Cardiometabolic Progress
Analysts have raised their price targets on Arrowhead Pharmaceuticals by roughly $6 to the mid $40s to low $60s range, citing the FDA approval of Redemplo, a strengthened commercial outlook in familial chylomicronemia syndrome and sHTG, and underappreciated long term cost and margin advantages. Analyst Commentary Bullish analysts view Redemplo's FCS approval as a key de-risking event that supports higher valuation multiples and justifies recent price target increases into the high $40s to low $60s range.Anlatı Güncellemesi • Dec 04
ARWR: Upcoming SHTG Data Will Likely Undermine Optimistic Cardiometabolic Expectations
Analysts have nudged their average price target on Arrowhead Pharmaceuticals higher to about $58 from $55, citing the FDA approval of Redemplo, expectations for a broader sHTG label, and underappreciated long term cost and margin advantages. Analyst Commentary Research coverage following the Redemplo approval has generally tilted positive, with several firms lifting their price targets and highlighting both the commercial opportunity in sHTG and Arrowhead's long term margin profile.Analiz Makalesi • Dec 02
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have continued their recent momentum with a 33% gain in the last...Anlatı Güncellemesi • Nov 20
ARWR: FDA Milestone Will Drive Cost Advantage In Cardiometabolic Markets
Analysts have raised Arrowhead Pharmaceuticals' fair value estimate from $47.50 to $55.00 per share after the FDA approved Redemplo and expressed increased confidence in the company's commercial execution and cost advantages. Analyst Commentary Following the recent FDA approval of Redemplo, analysts have provided updated perspectives on Arrowhead Pharmaceuticals' valuation and prospects.Anlatı Güncellemesi • Nov 06
ARWR: Expect Cost Efficiency To Drive Competitive Advantage In Upcoming Metabolic Trials
Analysts have significantly raised their price target for Arrowhead Pharmaceuticals, increasing it from $38 to $61 per share. They cite structural cost advantages and an underappreciated long-term gross margin potential as key factors for this change.Anlatı Güncellemesi • Oct 22
Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships
Arrowhead Pharmaceuticals' analyst price target has been raised from $45 to $47.50 per share. Analysts highlight the company's structural cost advantages and improved margin outlook.Analiz Makalesi • Oct 07
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You
Despite an already strong run, Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have been powering on, with a...Anlatı Güncellemesi • Oct 05
RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
Analysts have slightly lowered their price target for Arrowhead Pharmaceuticals from $46.15 to $45.00, citing ongoing concerns following recent strategic divestitures by partners and modest shifts in the company's projected financials. Analyst Commentary Recent analyst research provides a mixed outlook for Arrowhead Pharmaceuticals following notable events involving partner Sarepta Therapeutics.Anlatı Güncellemesi • Sep 08
RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
The consensus price target for Arrowhead Pharmaceuticals has increased modestly as its Future P/E has risen and Net Profit Margin has declined, resulting in a new analyst fair value of $46.15. What's in the News Arrowhead Pharmaceuticals announced a major global licensing and collaboration agreement with Novartis for ARO-SNCA, its preclinical siRNA therapy for synucleinopathies such as Parkinson’s Disease; the deal includes a $200 million upfront payment to Arrowhead, potential milestones up to $2 billion, and future royalties, with closing expected in the second half of 2025 (Key Developments).CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$320m |
| Mar 31 2026 | n/a | n/a | -US$301m |
| Dec 31 2025 | n/a | n/a | US$202m |
| Sep 30 2025 | US$9m | US$981k | -US$2m |
| Jun 30 2025 | n/a | n/a | -US$148m |
| Mar 31 2025 | n/a | n/a | -US$144m |
| Dec 31 2024 | n/a | n/a | -US$640m |
| Sep 30 2024 | US$12m | US$951k | -US$599m |
| Jun 30 2024 | n/a | n/a | -US$539m |
| Mar 31 2024 | n/a | n/a | -US$471m |
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 9.03M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 14.74M ).
Tazminat ve Kazançlar: Chris 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Chris Anzalone (57 yo)
18.8yrs
Görev süresi
US$9,029,861
Tazminat
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007 and serves as its Chairman. He serves a...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 18.8yrs | US$9.03m | 2.69% $ 313.9m | |
| Chief Financial Officer | 1.3yrs | US$2.33m | 0.0091% $ 1.1m | |
| COO & Secretary | 4.2yrs | US$3.03m | 0.24% $ 28.0m | |
| Chief Medical Officer and Head of R&D | no data | US$2.97m | 0.16% $ 18.8m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | Veri yok | Veri yok | |
| Chief Scientific Officer | less than a year | Veri yok | Veri yok | |
| Head of Investor Relations & VP | no data | Veri yok | Veri yok | |
| Director of Communications | 21.1yrs | Veri yok | Veri yok | |
| Chief Medical Scientist | 2.6yrs | US$16.34m | Veri yok | |
| Head of Toxicology & VP | no data | Veri yok | Veri yok | |
| Head of Tax | 4.7yrs | Veri yok | Veri yok | |
| SVP of Cardiovascular & Head of Metabolic Franchise | 1.8yrs | Veri yok | Veri yok |
3.4yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim: ARWR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 18.8yrs | US$9.03m | 2.69% $ 313.9m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | Veri yok | Veri yok | |
| Independent Director | 14.8yrs | US$428.18k | 0.073% $ 8.6m | |
| Independent Lead Director | 8.7yrs | US$438.18k | 0.035% $ 4.0m | |
| Member of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 16.1yrs | US$420.68k | 0.043% $ 5.1m | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 4.3yrs | US$424.43k | 0.020% $ 2.3m |
14.8yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ARWR 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 14.8 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/11 14:06 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/09/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Arrowhead Pharmaceuticals, Inc. 28 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Ying Huang | Barclays |
| Jason Matthew Gerberry | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |